DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer

Sponsor
Xijing Hospital
Study ID
NCT05050760
Status
Unknown

Conditions

  • ESCC

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab 200mg IV D1，Q3W,and preoperative therapy with three cycles.
  • DCF — DRUG
    DCF:Oxaliplatin (85mg/ m\^2, IV D1,Q3W.Docetaxel: 60 mg/m\^2 intravenous infusion for 60 minutes, D1,Q3W.Tegafur:BSA\<1.25\^2,40 mg/time,1.25\^2\<BSA\<1.5\^2,50 mg/time,BID ,after breakfast and dinner, continuous administration for 14 days, rest for 7 days, as a treatment cycle;Repeat every 3 weeks

Study Details

To evaluate the safety and feasibility of DCF combined with camrelizumab in the treatment of locally advanced ESCC

Key Dates

Start date
Sep 1, 2021
Status verified
Aug 2022
Primary completion
Dec 31, 2023
Completion
Dec 31, 2023

Study Design

Enrollment
55 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH

Arms

  • Experimental: The experimental group
    Drug：DCF+Camrelizumab Camrelizumab:200mg/time,IV,Q3W

Primary Outcome Measure

Safety and Feasibility（Incidence of Treatment-Emergent Adverse Events） [ Time Frame: 12months ]

Central Contacts

Related Studies